Publications - IR Sant Pau

Search

01/11/2025 Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial

Ballesteros, PA, García-Carbonero, I, Gonzalez, EE, Marin, AP, Lorente, D, de Liaño, AG, Ortega, EM, Colomo, LJ, Puente, J, Gonzalez, I, Calvo, OF, Palacios, GA, Mendizabal, I, Navarro, EP, Domínguez, JID, Esteban-Villarrubia, J, Billalabeitia, EG, Oria, GAD. Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3696. PMID:. IF:65.400(Q1/1D).

01/11/2025 Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry

España, MAG, Calle, SG, Flores, EG, Sosa, MM, Tocino, RV, Plazas, JG, Monteagudo, RF, Aguilera, MJS, Herrero, MDRM, Gargia, TG, Zafra, GM, Arévalo, MA, Orozco, EJ, Manrique, ACV, Alfonso, PG, Montes, AF, Ninerola, RQ, de Castro, EM, Verdaguer, H, García, RV. Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1362. PMID:. IF:65.400(Q1/1D).

01/11/2025 Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)

Kuboki, Y, Pietrantonio, F, Salvatore, L, Meriggi, FA, Modest, DP, Yaeger, R, Ruiz, E, Taieb, J, Karamouzis, MV, Esaki, T, Kim, TW, Cremolini, C, Strickler, JH, Masuishi, T, Paez, D, Chan, E, Chao, J, Tran, Q, Fakih, M, Hong, DS. Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1317. PMID:. IF:65.400(Q1/1D).

01/11/2025 Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment

Ahrens, M, Haanen, JBAG, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Rottey, S, Floercken, A, Rodriguez, CS, Rey, JPM, Burkholder, I, Hartmann, A, Bergmann, L. Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3211. PMID:. IF:65.400(Q1/1D).

01/11/2025 Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Sanborn, RE, Zhou, CC, Tang, KJ, Cho, BC, Cheng, S, Popat, S, Ono, A, Lu, S, Majem, M, Aguilar, A, Campelo, MDG, Hayashi, H, Lee, KY, Lee, SH, Delmonte, A, Alatorre-Alexander, J, Richardson, G, Santos, V, Dooms, C, Sabari, JK, Shu, CA, Girard, N, Mansfield, AS, Park, K, Xia, YC, Bhattacharya, A, Buyukkaramikli, N, Perualila, N, Diels, J, Acharya, S, Chandler, C, Proskorovsky, I, Dearden, L, Wortman-Vayn, H, Mahadevia, PJ, Knoblauch, RE, Agrawal, T, Baig, M, Felip, E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Targeted Oncology. 2025; 20(6)DOI:10.1007/s11523-025-01182-0. PMID:41184595. IF:4.000(Q2/3D).

01/11/2025 Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024

Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).

01/11/2025 Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study

Muñoz-Couselo, E, Berciano-Guerrero, MA, Crespo, G, Castaño, AG, Manzano, JL, Miguel, PAD, Rosa, CA, Cerezuela-Fuentes, P, Puértolas, T, Sanz, LG, Medina, J, Cunquero-Tomás, A, Majem, M, Fernández, LA, Espinosa, E, Bellido, L, Soria, A, Bujosa, A, Algarra, SM, Marquez-Rodas, I. Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2263. PMID:. IF:65.400(Q1/1D).

01/11/2025 Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer

Bergmann, L, Albiges, L, Ahrens, M, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Floercken, A, Rodriguez, CS, Rey, JPM, Gruenwald, V, Burkholder, I, Hartmann, A, Haanen, JBAG. Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3216. PMID:. IF:65.400(Q1/1D).

01/11/2025 International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study

Chen, TWW, Giani, C, Ljevar, S, Reinhorn, D, Denu, R, Bhadri, VA, Jaeger, R, Ibrahim, T, D'Ambrosio, L, Bae, S, Han, I, Garcia, AS, Abreu, MH, Ribeiro, MFSA, Mariuk-Jarema, A, Yang, V, Sbaraglia, M, Antonescu, C, Baldi, GG, Stacchiotti, S. International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3306. PMID:. IF:65.400(Q1/1D).

01/11/2025 Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort

Cerna, JGY, Mirallas, O, Garces, VN, Puerto, DAG, Velilla, G, Pastor, PG, Puga, TG, Salgado, MAV, Martínez, A, Gonzalez, AH, Sorolla, MA, Di Muzio, A, González, M, Martinez-Garcia, MJ, Villacampa, G, Balana, C, Galceran, JC, Dienstmann, R, Sanchez, JMS, Vieito, M. Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1270. PMID:. IF:65.400(Q1/1D).

01/11/2025 Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study

Muñiz, NH, Strauss, S, Redondo, A, Palmerini, E, Gaffaro, GJM, Chamberlain, FE, Martinez, V, Ibrahim, T, Trufero, JM, Morales, CMV, Billalabeitia, EG, Lleida, RT, Jiménez, CL, Mukherjee, U, Wan, S, Ramos, R, Garcia, AMG, Moura, DD, Martin-Broto, J. Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3296. PMID:. IF:65.400(Q1/1D).

01/11/2025 Magnitude of clinical benefit of cancer medicines in curative setting and health technology assessment decisions in Europe

Hwang, T, Kesselheim, A, Tibau, A. Magnitude of clinical benefit of cancer medicines in curative setting and health technology assessment decisions in Europe. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2893. PMID:. IF:65.400(Q1/1D).

01/11/2025 Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021

Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).

01/11/2025 Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients

Lopez, JS, Besora, CP, Malaret, M, Joaquín, AB, Recio, SM, Momblan, AM, Dalmau, GM, Majem, M. Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3451. PMID:. IF:65.400(Q1/1D).

01/11/2025 Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma

Blay, JY, Lleida, RT, Martin-Broto, J, Caetano, C, De Haan, JJ, Debruyne, C, Desar, I, Duffaud, F, Gelderblom, H, Gennigens, C, Italiano, A, Colomo, LJ, Lapeire, L, Mazzeo, F, Philip, J, Striefler, JK, Svobodova, M, Tala, I, Morales, CMV, Stacchiotti, S. Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3359. PMID:. IF:65.400(Q1/1D).

01/11/2025 CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas

Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).

01/11/2025 Isocitrate dehydrogenase 1 (IDH1) mutation testing in the phase III study of ivosidenib vs placebo in IDH1-mutant conventional chondrosarcoma (CHONQUER)

Stacchiotti, S, Yonemori, K, Beato, CM, Campos, FAB, Conley, AP, Debruyne, C, Endo, M, Hiraga, H, Kichenadasse, G, Laptewicz, M, Lleida, RT, Morais, ANR, Yoshihiro, N, Pereira, C, Salawu, AT, Takenaka, S, Tanaka, K, Tinoco, G, Vianna, KM, Bovée, JVMG. Isocitrate dehydrogenase 1 (IDH1) mutation testing in the phase III study of ivosidenib vs placebo in IDH1-mutant conventional chondrosarcoma (CHONQUER). ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3355. PMID:. IF:65.400(Q1/1D).

01/11/2025 Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial

Molasiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, LS, Bonizzoni, E, Vazquez, EB, Buchler, T, Cheng, Y, Christoph, DCC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanova, M, Aapro, MS. Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3413. PMID:. IF:65.400(Q1/1D).

01/10/2025 Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK plus Non-Small Cell Lung Cancer (NSCLC) in Spain

Bernabé, R, De Castro, J, Collado, R, Escudero, V, Gutiérrez, F, Arranz, S, Gordo, R, Arroyo, I, Majem, M. Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK plus Non-Small Cell Lung Cancer (NSCLC) in Spain. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%

Johnson, ML, Arriola, E, Kato, T, Girard, N, Gadgeel, S, Tarruella, MM, Newsom-Davis, T, Polaczek, M, Chen, X, Stefaniak, K, Lowery, C, Angra, N, Doherty, G, Ahn, MJ. Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients With Lung Cancer

Lopez, JS, Besora, CP, Verge, MM, Joaquin, AB, Recio, SM, Pastor, M, Fierro, JP, Martinez-Esparza, EH, Martinez-Momblan, MA, Majem, M. Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients With Lung Cancer. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 NIVIPI-Brain: Phase 2 Study of Nivolumab plus Ipilimumab Combined With Chemotherapy in NSCLC With Synchronous Brain Metastases

Nadal, E, Cantero, A, Paz-Ares, L, Ortega, AL, Barba, A, Iranzo, P, Domine, M, Garcia, J, Blasco, A, Campelo, RG, Rodriguez-Abreu, D, Castro, RL, Vidal, OJ, Tena, I, Diz, P, Provencio, M, Simo, M, Vilariño, N, Navarro,, Bruna, J. NIVIPI-Brain: Phase 2 Study of Nivolumab plus Ipilimumab Combined With Chemotherapy in NSCLC With Synchronous Brain Metastases. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features

Torresan, S, Torres, CSD, Caramella, C, Ambrosini, P, Gomez-Randulfe, I, Monaca, F, Ribera, A, Goudsmit, A, Michelini, A, Segui, V, Insa, A, Martorell, PM, Romero-Sola, G, Caro-Consuegra, R, Mirallas, O, Priano, I, Valdivia, A, Masfarré, L, Iranzo, P, Martinez-Marti, A, Cedres, S, Catot, S, Sequeira, T, Callejo, A, Bearz, A, Barba, A, Antoñanzas, M, Sais, E, Baena, J, Brandao, M, Mosteiro, M, Vilariño, N, Gambardella, V, Moran, T, Occhipinti, M, Califano, R, Pardo, N, Felip, E, Rocha, P. Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 Benefits of Adjuvant Alectinib in ALK plus Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System

De Castro, J, Bernabé, R, Escudero, V, Gutiérrez, F, Majem, M, Gordo, R, Arroyo, I, Arranz, S, Collado, R. Benefits of Adjuvant Alectinib in ALK plus Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress

Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregon, M, Campos, B, Coves, J, De Castro, J, Domènech, M, Domine, M, Campelo, RG, Gozálvez, CL, Huidobro, G, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares, A, Reguart, N, Sala, MA, Medina, K, Vilà, L, Massuti, B. ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Sanchez, AYC, Bustillos, A, Herraez-Baranda, L, Barata, T, Young, F, Majem, M. IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study

Grohé, C, Wu, YL, Tsuboi, M, Majem, M, John, T, Bolanos, A, Taylor, R, Sandelin, M, Herbst, RS. Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2025 A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations

Wang, M, Jänne, PA, Doucet, L, Fan, Y, Lv, D, Sun, M, Huang, D, Greillier, L, Planchard, D, Hong, Q, Mazieres, J, Felip, E, Li, X, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Ferreira, BP, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, R, Zalcman, G, Carpeño, JD, Di Noia, V, Parra, HS, Streich, G, Lee, D, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquín, AB, Liu, G, Antonuzzo, L, Fernandez-Hinojal, G, Le, X, Zheng, L, Yang, JCH. A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/09/2025 Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, JS, Majer, IM, Pietrantonio, F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00352-3. PMID:40812325. IF:35.900(Q1/1D).

01/09/2025 Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Audisio, A, Gallio, C, Velenik, V, Meillat, H, Ruiz-Garcia, E, Riesco, MC, Alecha, JS, Rasschaert, G, Carvalho, C, Randrian, V, Kirac, I, Hernando, J, Artac, M, O'Connor, JM, Waldhorn, I, Braam, PM, Shamseddine, A, Moretto, R, de la Pinta, C, De Felice, F, Dulskas, A, Lopez-Bravo, DP, Vanden Bulcke, A, Bock, F, Deleporte, A, van den Eynde, M, Geboes, KP, Loi, M, Messina, M, Houlze-Laroye, C, Puccini, A, Pastorino, A, Papamichael, D, Fiore, M, Sur, D, Eid, M, Antoun, C, Salati, M, Garajova, I, Jakubauskas, M, Tomasek, J, Pinto, CMS, Schwingel, J, Morano, F, Adams, RA, Dermine, A, Chau, A, Javed, MA, Ghidini, M, Fiorica, F, Montenegro, P, Petrillo, A, Spolverato, G, Margalef, NM, Diaz, M, Baratelli, C, Puleo, F, Karampeazis, A, Sert, F, Gilliaux, Q, De Stefano, A, Liberale, G, Moretti, L, Martinive, P, Thomas, VD, Staggs, V, Saad, ED, Van Laethem, JL, Sclafani, F. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology. 2025; 11(9)DOI:10.1001/jamaoncol.2025.2026. PMID:40638097. IF:20.100(Q1/1D).

10/02/2026 Subcutaneous administration of an endocrine-mimetic platform allows for prolonged tumor uptake of a tumor targeting protein

Alamo, P, López-Laguna, H, Favaro, MTP, Gallardo, A, Alba-Castellon, L, Villaverde, A, Mangues, R, Vázquez, E. Subcutaneous administration of an endocrine-mimetic platform allows for prolonged tumor uptake of a tumor targeting protein. INTERNATIONAL JOURNAL OF PHARMACEUTICS. 2026; 690DOI:10.1016/j.ijpharm.2026.126585. PMID:41521013. IF:5.200(Q1/2D).

01/03/2025 Surpassing protein specificity in biomimetics of bacterial amyloids

Sanchez, JM, Voltà-Durán, E, Parladé, E, Mangues, R, Villaverde, A, Vázquez, E, Unzueta, U. Surpassing protein specificity in biomimetics of bacterial amyloids. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2025; 296DOI:10.1016/j.ijbiomac.2025.139635. PMID:39788253. IF:8.500(Q1/1D).

15/10/2023 High-precision targeting and destruction of cancer-associated PDGFR-ß(+) stromal fibroblasts through self-assembling, protein-only nanoparticles.

Voltà-Durán E, Alba-Castellón L, Serna N, Casanova I, López-Laguna H, Gallardo A, Sánchez-Chardi A, Villaverde A, Unzueta U, Vázquez E, Mangues R. High-precision targeting and destruction of cancer-associated PDGFR-ß(+) stromal fibroblasts through self-assembling, protein-only nanoparticles.. Acta Biomaterialia. 2023; 170DOI:10.1016/j.actbio.2023.09.001. PMID:37683965. IF:9.400(Q1/1D).

01/02/2026 Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study

Hernández-Sánchez, A, Ramiro, AV, Sträng, E, Turki, AT, Abáigar, M, Versluis, J, Thomas, I, Sobas, M, Elicegui, JM, Castellani, G, Benner, A, Azibeiro, R, Tettero, JM, Mecklenbrauck, R, Martínez-López, J, Pratcorona, M, Mills, KI, Sanz, G, Voso, MT, Sören, L, Röllig, C, Thiede, C, Metzeler, KH, Döhner, K, Heuser, M, Haferlach, T, Valk, PJM, Russell, N, Hernández-Rivas, JM, Huntly, B, Ossenkoppele, G, Döhner, H, Bullinger, L. Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study. LEUKEMIA. 2026; 40(2)DOI:10.1038/s41375-025-02851-9. PMID:41535568. IF:13.400(Q1/1D).

08/01/2026 Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations

Charalampopoulou, S, Ramos-Campoy, S, Duran-Ferrer, M, Puiggros, A, Kamaso, J, Nguyen-Khac, F, Rigolin, GM, Cuneo, A, Collado, R, García-Serra, R, Haferlach, C, Ortega, M, Abrisqueta, P, Bosch, F, Zenz, T, Blanco, ML, Salgado, R, García-Malo, MD, Gimeno, E, Lopez-Guillermo, A, Campo, E, Etter, L, Schoumans, J, Espinet, B, Martin-Subero, JI. Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations. Hemasphere. 2026; 10(1)DOI:10.1002/hem3.70211. PMID:41523081. IF:14.600(Q1/1D).

03/11/2025 Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Torres-Esquius, S, Gabarros-Subira, M, Rivero, ME, López, GR, Mañó, LG, Lopez, F, Fernandez, C, Guijarro, F, Díaz-Beyá, M, Canela, MP, Acha, P, Jáuregui, SN, Tuset, E, Palomo, L, Valcarcel, D, Albareda, FB, Jerez, A, Montoro, MJ. Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults. BLOOD. 2025; 146DOI:10.1182/blood-2025-4998. PMID:. IF:23.100(Q1/1D).

03/11/2025 Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Turki, A, Dall'Olio, D, Carota, L, Polizzi, S, Morote, M, Della Porta, M, Zhao, YM, Lanino, L, Sobas, M, Zhao, YQ, Sanchez, AH, Eric, S, Gimenez, LT, Abáigar, M, Elicegui, JM, Ramiro, AV, Dohner, K, Tettero, J, Esteve, J, Martinez-Lopez, J, Metzeler, K, Haferlach, T, Lehmann, S, Pratcorona, M, Thiede, C, Versluis, J, Mecklenbrauck, R, Heuser, M, Benner, A, Huntley, B, Rivas, JMH, Ossenkoppele, G, Döhner, H, Castellani, G, Bullinger, L. Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia. BLOOD. 2025; 146DOI:10.1182/blood-2025-451. PMID:. IF:23.100(Q1/1D).

01/05/2025 Comparative analysis of NGS and dPCR for measurable residual disease monitoring in intensively treated acute myeloid leukemia patients

Ramil, G, Artigas, A, Giné, A, Oñate, G, Castellet, H, Díaz-Beyá, M, Tormo, M, Cervera, M, Coll, R, Martínez-Serra, J, Vives, S, García-Guiñón, A, Mascaró, M, Gómez, L, García-Avila, S, Vall-Llovera, F, Gómez, R, Arnan, M, Salamero, O, Garrido, A, Esteve, J, Nomdedéu, J, Sierra, J, Pratcorona, M. Comparative analysis of NGS and dPCR for measurable residual disease monitoring in intensively treated acute myeloid leukemia patients. ANNALS OF HEMATOLOGY. 2025; 104(1)DOI:. PMID:. IF:2.400(Q2/5D).

01/10/2025 Complementary Role of IHC in ALK Fusion Detection: A Validation Study of NSCLC NGS-Based Screening in Seven Laboratories

Clavé, S, Montironi, C, Oliveras, G, Varela, M, Catasús, L, Sese, M, Hernández-Gallego, A, Teixido, C, Urbizu, A, González-Vidal, A, Pijuan, L, Sansano, I, Baixeras, N, Vásquez, C, Fuertes, B, Sánchez-Güerri, I, Lopez-Vilaro, L, Mate, JL, Bellosillo, B, Hernández-Losa, J, Muñoz-Mármol, AM. Complementary Role of IHC in ALK Fusion Detection: A Validation Study of NSCLC NGS-Based Screening in Seven Laboratories. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/09/2025 Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis

Herrera, IC, Fabregó, IE, Cols, LC, Lladó, MC, Vidal, AG, Martín, LF, Mariscal, IE, Arango, SMR, Metrallé, SCS, Alcañiz, AG. Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis. VIRCHOWS ARCHIV. 2025; 487DOI:. PMID:. IF:3.100(Q2/3D).